Radiotherapy & Oncology
Volume 97, Issue 3 , Pages 462-466 , December 2010

Which α/β ratio and half-time of repair are useful for predicting outcomes in prostate cancer?

  • Philippe Nickers

      Affiliations

    • Department of Radiation Oncology, University Hospital of Liège, Belgium
    • Department of Radiation Oncology, Centre Oscar Lambret, Lille, France
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology, Centre Oscar Lambret, 3, Rue Frederic Combemale, 59000 Lille, France.
    • ,
  • Johanne Hermesse

      Affiliations

    • Department of Radiation Oncology, University Hospital of Liège, Belgium
    • ,
  • Jean-Marie Deneufbourg

      Affiliations

    • Department of Radiation Oncology, University Hospital of Liège, Belgium
    • Honorary.
    • ,
  • Sophie Vanbelle

      Affiliations

    • Department of Biomedical Statistics, University Hospital of Liège, Belgium
    • ,
  • Eric Lartigau

      Affiliations

    • Department of Radiation Oncology, Centre Oscar Lambret, Lille, France

Received 12 November 2009 ,Revised 21 June 2010 ,Accepted 22 June 2010.

References 

  1. Dasu A. Is the α/β value for prostate tumours low enough to be safely used in clinical trials?. Clin Oncol. 2007;19:289–301
  2. Miles EF, Lee WR. Hypofractionation for prostate cancer: a critical review. Semin Radiat Oncol. 2008;18:41–47
  3. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  4. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumours show high sensitivity to fractionation (low α/β), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6–13
  5. Williams WS, Taylor JM, Liu N, et al. Use of individual fraction size data from 3756 patients to directly determine the α/β ratio of prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:24–33
  6. Mirabell R, Roberts SA, Zubizarreta E, Hendry JH. Dose fractionation sensitivities of low/middle/high risk cancer deduced from seven international primary institutional datasets. Int J Radiat Oncol Biol Phys. 2009;75:S81
  7. Pollack A, Buyyounouski M, Horwitz E, et al. Hypofractionation for prostate cancer: interim results of a randomized trial. Int J Radiat Oncol Biol Phys. 2009;75:S81
  8. Wang JZ, Guerrero M, Li XA. How low is the α/β ratio for prostate cancer?. Int J Radiat Oncol Biol Phys. 2003;55:194–203
  9. Wang JZ, Li XA. Impact of tumour repopulation on radiotherapy planning. Int J Radiat Oncol Biol Phys. 2005;61:220–227
  10. Nahum AE, Mosvas B, Horwitz EM, Strobbe CC, Chapman JD. Incorporating clinical measurements of hypoxia into tumour local control modelling of prostate cancer: implications for the α/β ratio. Int J Radiat Oncol Biol Phys. 2003;57:391–401
  11. Vergis R, Corbishley CM, Norman AR, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol. 2008;9:342–351
  12. Fowler J, Chappell R, Ritter M. Is α/β for prostate tumours really low?. Int J Radiat Oncol Biol Phys. 2001;50:1021–1031
  13. Carlone M, Wilkins D, Nyiri B, Raaphorst P. Comparison of alpha/beta estimates from homogeneous and heterogeneous tumour control models for early stage prostate cancer. Med Phys. 2004;31:1176–1182
  14. Schinkel C, Carlone M, Warkentin B, Fallone BG. Analytic investigation into effect of population heterogeneity on parameter ratio estimates. Int J Radiat Oncol Biol Phys. 2007;69:1323–1330
  15. Nickers P, Coppens L, de Leval J, Jansen N, Deneufbourg JM. 192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: a phase II trial. Radiother Oncol. 2006;79:329–334
  16. Nickers P, Coppens L, Beauduin M, Darimont M, de Leval J, Deneufbourg JM. Feasibility study combining low dose rate 192Ir brachytherapy and external beam radiotherapy aiming at delivering 80–85Gy to prostatic adenocarcinoma. Radiother Oncol. 2000;55:41–47
  17. Nickers P, Hermesse J, Jansen N. HDR or LDR in the radiation treatment of prostate cancer: identical results or toxicity rates?. Radiother Oncol. 2007;83:38;(S1)
  18. Dale RG. The use of small fraction numbers in high dose-rate gynaecological afterloading: some radiobiological considerations. Br J Radiol. 1990;63:290–294
  19. Albert Harris EK, Albert A. Survivorship analysis for clinical studies. New York: Dekker; 1997;
  20. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  21. D’Ambrosio DJ, Li T, Horwitz EM, Chen DY, Pollack A, Buyyounouski MK. Does treatment duration affect outcome after radiotherapy for prostate cancer?. Int J Radiat Oncol Biol Phys. 2008;72:1402–1407
  22. Perez CA, Michalski J, Mansur D, Lockett MA. Impact of elapsed treatment time on outcome of external-beam radiation therapy for localized carcinoma of the prostate. Cancer J. 2004;10:349–356
  23. D’Souza WD, Thames HD. Is the α/β ratio for prostate cancer low?. Int J Radiat Oncol Biol Phys. 2001;52:1–3
  24. Yeoh EE, Holloway RH, Fraser RJ, et al. Hypofractionated vs conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006;66:1072–1083
  25. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005;23:6132–6138
  26. Arcangeli G, Saracino B, Gomellini SA, et al. A phase III randomized study of high dose conventional vs. hypofractionated radiotherapy in patients with high risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;75:S79
  27. Bentzen SM, Ritter MA. The α/β ratio for prostate cancer: what is it, really?. Radiother Oncol. 2005;76:1–3
  28. Hoskin PJ, Motohashi K, Bownes P, Bryant L, Ostler P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol. 2007;84:114–120
  29. Pieters BR, de Back DZ, Koning CCE, Zwinderman AH. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiother Oncol. 2009;93:168–173
  30. Khor LY, Bae K, Pollack A. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol. 2007;8:912–920
  31. Che M, De Silvio M, Pollack A, et al. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. Int J Radiat Oncol Biol Phys. 2007;69:1117–1123

PII: S0167-8140(10)00390-7

doi: 10.1016/j.radonc.2010.06.006

Radiotherapy & Oncology
Volume 97, Issue 3 , Pages 462-466 , December 2010

Article Tools

* Image Usage & Resolution